Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
9.09
+0.30 (3.41%)
At close: May 15, 2026, 4:00 PM EDT
8.81
-0.28 (-3.08%)
After-hours: May 15, 2026, 7:38 PM EDT
Upstream Bio Employees
Upstream Bio had 75 employees as of December 31, 2025. The number of employees increased by 23 or 44.23% compared to the previous year.
Employees
75
Change (1Y)
23
Growth (1Y)
44.23%
Revenue / Employee
$44,293
Profits / Employee
-$2,090,187
Market Cap
494.68M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | 23 | 44.23% |
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| REGENXBIO | 371 |
| ProKidney | 231 |
| Neurogene | 131 |
| Ocugen | 116 |
| Assembly Biosciences | 73 |
| Prothena Corporation | 67 |
| Contineum Therapeutics | 51 |
UPB News
- 3 days ago - Upstream Bio price target lowered to $50 from $51 at Mizuho - TheFly
- 4 days ago - Upstream Bio reports Q1 revenue $1.03M, consensus $347,170 - TheFly
- 4 days ago - Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug - TheFly
- 4 weeks ago - Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - GlobeNewsWire
- 7 weeks ago - Upstream Bio downgraded to In Line from Outperform at Evercore ISI - TheFly
- 7 weeks ago - Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Upstream Bio Transcript: Leerink Global Healthcare Conference 2026 - Transcripts